KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Capital Expenditures: 2020-2025

Historic Capital Expenditures for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to $243,000.

  • Recursion Pharmaceuticals' Capital Expenditures fell 94.67% to $243,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 54.90%. This contributed to the annual value of $13.7 million for FY2024, which is 14.55% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Capital Expenditures stood at $243,000, which was down 92.29% from $3.1 million recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Capital Expenditures peaked at $19.4 million during Q1 2021, and registered a low of $243,000 during Q3 2025.
  • Over the past 3 years, Recursion Pharmaceuticals' median Capital Expenditures value was $2.1 million (recorded in 2023), while the average stood at $2.8 million.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Capital Expenditures soared by 2,738.60% in 2021 and then plummeted by 94.67% in 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Capital Expenditures (Quarterly) stood at $4.5 million in 2021, then soared by 78.74% to $8.0 million in 2022, then crashed by 74.09% to $2.1 million in 2023, then crashed by 37.20% to $1.3 million in 2024, then crashed by 94.67% to $243,000 in 2025.
  • Its Capital Expenditures stands at $243,000 for Q3 2025, versus $3.1 million for Q2 2025 and $1.8 million for Q1 2025.